RU2010145529A - Композиции гидрофобных производных таксана и их применение - Google Patents
Композиции гидрофобных производных таксана и их применение Download PDFInfo
- Publication number
- RU2010145529A RU2010145529A RU2010145529/15A RU2010145529A RU2010145529A RU 2010145529 A RU2010145529 A RU 2010145529A RU 2010145529/15 A RU2010145529/15 A RU 2010145529/15A RU 2010145529 A RU2010145529 A RU 2010145529A RU 2010145529 A RU2010145529 A RU 2010145529A
- Authority
- RU
- Russia
- Prior art keywords
- composition according
- composition
- paragraphs
- unsubstituted
- nanoparticles
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 85
- 230000002209 hydrophobic effect Effects 0.000 title claims abstract 13
- 239000002105 nanoparticle Substances 0.000 claims abstract 25
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims abstract 15
- 125000003118 aryl group Chemical group 0.000 claims abstract 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 9
- 102000014914 Carrier Proteins Human genes 0.000 claims abstract 8
- 108010078791 Carrier Proteins Proteins 0.000 claims abstract 8
- 125000000217 alkyl group Chemical group 0.000 claims abstract 5
- 102000009027 Albumins Human genes 0.000 claims abstract 4
- 108010088751 Albumins Proteins 0.000 claims abstract 4
- 229940123237 Taxane Drugs 0.000 claims abstract 4
- 150000001875 compounds Chemical class 0.000 claims abstract 4
- 125000001165 hydrophobic group Chemical group 0.000 claims abstract 4
- 150000003839 salts Chemical class 0.000 claims abstract 4
- 239000012453 solvate Substances 0.000 claims abstract 4
- 125000003342 alkenyl group Chemical group 0.000 claims abstract 3
- 125000000304 alkynyl group Chemical group 0.000 claims abstract 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 3
- 102000008100 Human Serum Albumin Human genes 0.000 claims abstract 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims abstract 2
- 125000002252 acyl group Chemical group 0.000 claims abstract 2
- 229940002612 prodrug Drugs 0.000 claims abstract 2
- 239000000651 prodrug Substances 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 230000003211 malignant effect Effects 0.000 claims 6
- 238000004090 dissolution Methods 0.000 claims 5
- 238000004128 high performance liquid chromatography Methods 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- 239000000839 emulsion Substances 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 241000288906 Primates Species 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 229920000249 biocompatible polymer Polymers 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 0 C*[C@@](C[C@@](CC1)[C@]1(C)C1C[C@](*)(C2)C(C)(C)C([C@]3*)=C(C)[C@]2OC([C@](*)[C@@](*(C)C(*)=O)c2ccccc2)=O)C1(C)C3=O Chemical compound C*[C@@](C[C@@](CC1)[C@]1(C)C1C[C@](*)(C2)C(C)(C)C([C@]3*)=C(C)[C@]2OC([C@](*)[C@@](*(C)C(*)=O)c2ccccc2)=O)C1(C)C3=O 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4400608P | 2008-04-10 | 2008-04-10 | |
| US61/044,006 | 2008-04-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010145529A true RU2010145529A (ru) | 2012-05-20 |
Family
ID=40456809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010145529/15A RU2010145529A (ru) | 2008-04-10 | 2008-09-12 | Композиции гидрофобных производных таксана и их применение |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JP2011517683A (OSRAM) |
| KR (2) | KR20150136137A (OSRAM) |
| RU (1) | RU2010145529A (OSRAM) |
| TW (1) | TW200942233A (OSRAM) |
| WO (1) | WO2009126175A1 (OSRAM) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| LT3311805T (lt) | 2005-08-31 | 2020-04-27 | Abraxis Bioscience, Llc | Kompozicijos, apimančios silpnai vandenyje tirpius farmacinius agentus ir priešmikrobinius agentus |
| ES2764100T3 (es) | 2009-04-15 | 2020-06-02 | Abraxis Bioscience Llc | Composiciones de nanopartículas exentas de priones y métodos |
| US9211283B2 (en) * | 2009-12-11 | 2015-12-15 | Biolitec Pharma Marketing Ltd | Nanoparticle carrier systems based on human serum albumin for photodynamic therapy |
| EP2552438B1 (en) | 2010-03-26 | 2016-05-11 | Abraxis BioScience, LLC | Methods of treatment of hepatocellular carcinoma |
| CA2794147A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma |
| BR112012024442A2 (pt) | 2010-03-29 | 2017-03-21 | Abraxis Bioscience Llc | métodos de tratamento de câncer |
| RU2576609C2 (ru) | 2010-06-04 | 2016-03-10 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы лечение рака поджелудочной железы |
| EP3056201A1 (en) | 2010-06-07 | 2016-08-17 | Abraxis BioScience, LLC | Combination therapy methods for treating proliferative diseases |
| EP2447268A1 (en) | 2010-10-29 | 2012-05-02 | INDENA S.p.A. | Crystalline form of 13-[(N-tert-butoxycarbonyl)-2'-O-hexanoyl-3-phenylisoserinyl]-10-deacetylbaccatin III |
| EP2773322A1 (en) | 2011-11-01 | 2014-09-10 | Celgene Corporation | Methods for treating cancers using oral formulations of cytidine analogs |
| WO2013085902A1 (en) | 2011-12-05 | 2013-06-13 | The University Of Texas M.D. | Combination therapy methods for treating an inflammatory breast cancer |
| HUE045661T2 (hu) | 2011-12-14 | 2020-01-28 | Abraxis Bioscience Llc | Polimer segédanyagok alkalmazása részecskék liofilizálásához vagy fagyasztásához |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| EP2968254B1 (en) | 2013-03-12 | 2020-04-22 | Abraxis BioScience, LLC | Methods of treating lung cancer |
| EP2968191B1 (en) | 2013-03-14 | 2021-06-16 | Abraxis BioScience, LLC | Methods of treating bladder cancer |
| WO2015195634A1 (en) | 2014-06-17 | 2015-12-23 | Celgne Corporation | Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| LT3313401T (lt) | 2015-06-29 | 2022-01-10 | Abraxis Bioscience, Llc | Nanodalelės, apimančios sirolimą ir albuminą, skirtos naudoti epitelioidinių ląstelių navikų gydymui |
| AU2016323770A1 (en) * | 2015-09-16 | 2018-03-29 | Dfb Soria, Llc | Delivery of drug nanoparticles and methods of use thereof |
| US11730736B2 (en) | 2017-11-06 | 2023-08-22 | Rapt Therapeutics, Inc. | Anticancer agents |
| BR112020018910A2 (pt) | 2018-03-20 | 2020-12-29 | Abraxis Bioscience, Llc | Métodos de tratamento de transtorno do sistema nervoso central através da administração de nanopartículas de um unibidor de mtor e de uma albumina |
| JP2022553426A (ja) | 2019-10-28 | 2022-12-22 | アブラクシス バイオサイエンス， エルエルシー | アルブミンおよびラパマイシンの医薬組成物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1245156C (zh) * | 1993-02-22 | 2006-03-15 | 美国生物科学有限公司 | 用于体内传送生物制品的方法及用于该方法的组合物 |
| US5916596A (en) * | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6749868B1 (en) * | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| NZ318300A (en) * | 1995-09-12 | 1999-08-30 | Liposome Co Inc | Hydrolysis-promoting taxane hydrophobic derivatives |
| DK1023050T3 (da) * | 1997-06-27 | 2013-10-14 | Abraxis Bioscience Llc | Nye formuleringer af farmakologiske midler, fremgangsmåder til fremstillingen deraf og fremgangsmåder til anvendelsen deraf |
| BR0104350A (pt) * | 2000-02-02 | 2002-01-02 | Univ Florida State Res Found | Taxanos de c10 acetato heterossubstituìdo como agentes antitumor |
| WO2006089207A2 (en) * | 2005-02-18 | 2006-08-24 | Abraxis Bioscience, Inc. | Drugs with improved hydrophobicity for incorporation in medical devices |
| WO2006091780A2 (en) * | 2005-02-24 | 2006-08-31 | Elan Pharma International Limited | Nanoparticulate formulations of docetaxel and analogues thereof |
-
2008
- 2008-09-12 KR KR1020157031393A patent/KR20150136137A/ko not_active Ceased
- 2008-09-12 KR KR1020107025259A patent/KR20100133475A/ko not_active Ceased
- 2008-09-12 RU RU2010145529/15A patent/RU2010145529A/ru unknown
- 2008-09-12 TW TW097135271A patent/TW200942233A/zh unknown
- 2008-09-12 JP JP2011503961A patent/JP2011517683A/ja active Pending
- 2008-09-12 WO PCT/US2008/076179 patent/WO2009126175A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011517683A (ja) | 2011-06-16 |
| TW200942233A (en) | 2009-10-16 |
| WO2009126175A1 (en) | 2009-10-15 |
| KR20100133475A (ko) | 2010-12-21 |
| KR20150136137A (ko) | 2015-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010145529A (ru) | Композиции гидрофобных производных таксана и их применение | |
| JP2011517683A5 (OSRAM) | ||
| US20250120947A1 (en) | Compounds and methods to sensitize cancer cells to cisplatin | |
| JP4344234B2 (ja) | タキソール増強剤化合物 | |
| AU2009308511B2 (en) | Transition metal complexes of a bis[thiohydrazide amide] compound | |
| US20030195258A1 (en) | Taxol enhancer compounds | |
| RU2011122729A (ru) | Окисленные соединения липидов и их применение | |
| JPH08500112A (ja) | タキソールと組み合わせるプロテインキナーゼ阻害剤および関連化合物 | |
| RU2000131183A (ru) | Производные оксииминоалкановой кислоты | |
| CA2494049A1 (en) | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof | |
| RU2014112108A (ru) | Составы с производными децитабина | |
| RU2005132309A (ru) | Мицелярный препарат, содержащий малорастворимый в воде противораковый агент и новый блоксополимер | |
| US20250325686A1 (en) | Peptide-linked drug delivery system | |
| RU2012150501A (ru) | Противораковые стероидные лактоны, ненасыщенные в положении 7(8) | |
| CA3082786A1 (en) | Stable compositions of pegylated carfilzomib compounds | |
| CN101437505A (zh) | 去甲二氢愈创木酸衍生物在治疗抗药性癌症、病毒和微生物感染中的用途 | |
| EP2958569B1 (fr) | Hétérocycles phosphorés analogues de sucres à activité antimétastatique | |
| RU2220965C2 (ru) | Сульфонамидозамещенные соединения и фармацевтический состав на их основе | |
| WO2011001109A1 (fr) | Methodes et compositions pour le traitement de cancers | |
| RU93005114A (ru) | Пенемовые соединения и фармацевтическая композиция на их основе | |
| US20200140375A1 (en) | Compositions and methods for treating conditions associated with altered tca cycle metabolism | |
| RU2006146051A (ru) | Новые соединения, фармацевтические композиции на их основе и способы применения | |
| WO2018055136A1 (fr) | Utilisation des harringtonines dans le traitement du cancer du sein, notamment triple-négatif | |
| WO2007147373B1 (en) | Pharmaceutical composition for injectional, particularly targeted local administration | |
| WO2024118760A1 (en) | Peptide-linked drug delivery system |